NeoGraph Analytics
Medical DevicesNorth America2023 – 2032

Brachytherapy Market Size, Share and Trends Analysis

Global brachytherapy market size was $1.6B in 2023 and is projected to reach $2.58B by 2032 at a 5.5% CAGR. Includes regional analysis, key players, and market trends for cancer treatment devices.

Revenue, 2023

$1.6B

Forecast, 2032

$2.6B

CAGR, 2024-2032

5.5%

Report Coverage

North America

Code: brachytherapy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The brachytherapy market is experiencing robust growth driven by technological advancements in radiation oncology and rising cancer incidence globally. This precision treatment modality offers targeted tumor control with reduced side effects compared to conventional radiation therapy.

Market Stage

Growing

Adoption Level

Growing

Key Trends

Integration of AI for real-time treatment planningExpansion of HDR brachytherapy applicationsGrowth in low-cost brachytherapy systems for emerging marketsIncreased focus on patient-specific dosimetry
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 5.5%

Base Year (2023)

$1.7B

Forecast (2032)

$2.6B

CAGR (2024-2032)

5.5%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 45.0%CAGR: 4.5%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 5.0%

Largest market: Germany

03

Market Dynamics

  • Rising global cancer incidence rates
  • Advancements in radioactive source technologies
  • Increasing preference for minimally invasive cancer treatments
  • Government initiatives for cancer care infrastructure
04

Market Segmentation

By Type

  • High Dose Rate (HDR)
  • Low Dose Rate (LDR)
  • Pulsed Dose Rate (PDR)

By Application

  • Prostate Cancer
  • Cervical Cancer
  • Breast Cancer
  • Gynecological Cancers
  • Other Applications

By End User

  • Hospitals
  • Cancer Centers
  • Ambulatory Surgical Centers
05

Regional Analysis

1

North America

Lead: United States
CAGR: 4.5%Share: 45.0%

Dominant market due to advanced healthcare infrastructure and high cancer prevalence rates.

2

Europe

Lead: Germany
CAGR: 5.0%Share: 30.0%

Stable growth driven by strong reimbursement policies and widespread adoption in major healthcare systems.

3

Asia Pacific

Lead: China
CAGR: 7.5%Share: 25.0%

Fastest-growing region due to rising cancer incidence and expanding healthcare investments.

Country-Level Analysis

CountryShareGrowth
United States
35.0%
+4.0%
Germany
15.0%
+5.0%
Japan
10.0%
+6.0%
China
8.0%
+7.5%
06

Competitive Landscape

E

Elekta AB

Sweden

Leader4.5B

Global leader in radiation therapy solutions with comprehensive brachytherapy portfolio

Elekta PreciseRaySearch Laboratories
V

Varian Medical Systems

USA

Leader7.2B

Major provider of HDR brachytherapy systems and treatment planning software

Varian AriaBrachytherapy Planning System
I

Isoray Inc.

USA

Challenger

Specializes in LDR brachytherapy solutions and radioactive seed manufacturing

N

Nucletron

Netherlands

Follower

Provides HDR brachytherapy systems and specialized treatment planning tools

O

Oncor Medical

USA

Follower

Focuses on advanced afterloading systems for HDR brachytherapy

07

Recent Developments

25
2025Elekta AB

Launch of AI-powered brachytherapy treatment planning platform with real-time dose optimization

24
2024Varian Medical Systems

Strategic partnership with AI startup to enhance brachytherapy treatment planning accuracy

24
2024Nucletron

FDA approval for new compact HDR brachytherapy system with enhanced safety features

23
2023Oncor Medical

Introduction of remote-controlled afterloader system for improved clinician safety

23
2023Isoray Inc.

Expanded brachytherapy training programs for oncologists in emerging markets

08

Regulatory Landscape

FDA 510(k) clearance for new brachytherapy devicesEU MDR compliance requirements for medical devicesISO 13485 certification for quality management systems
09

Frequently Asked Questions

The global brachytherapy market was valued at $1.6 billion in 2023 and is projected to reach $2.58 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 5.5% during the forecast period 2024-2032.
The prostate cancer application segment held the largest market share of 40% in 2023.
Asia Pacific is the fastest-growing region with a projected CAGR of 7.5% from 2024-2032.